Literature DB >> 10651149

Electrophysiological effects of fluoxetine in mammalian cardiac tissues.

P Pacher1, J Magyar, P Szigligeti, T Bányász, C Pankucsi, Z Korom, Z Ungvári, V Kecskeméti, P P Nánási.   

Abstract

Fluoxetine is a widely used antidepressant compound having selective serotonin reuptake inhibitor properties. In this study, the actions of fluoxetine were analyzed in guinea pig, rat, rabbit and canine ventricular myocardiac preparations using conventional microelectrode and whole cell voltage clamp techniques. Low concentrations of fluoxetine (1-10 micromol/l) caused significant shortening of action potential duration (APD) and depression of the plateau potential in guinea pig and rabbit papillary muscles and single canine ventricular myocytes. In rat papillary muscle, APD was not affected by fluoxetine (up to 100 micromol/l), however, the drug decreased the force of contraction with EC50 of 10 micromol/l. Fluoxetine (10 micromol/l) also decreased the maximum velocity of depolarization and action potential overshoot in each species studied. At this concentration no effect was observed on the resting membrane potential; high concentration (100 micromol/l), however, caused depolarization. In voltage clamped canine ventricular myocytes, fluoxetine caused concentration-dependent block of the peak Ca2+ current at 0 mV with EC50 of 5.4+/-0.94 micromol/l and Hill coefficient of 1.1+/-0.14 (n=6). In addition, 10 micromol/l fluoxetine shifted the midpoint of the steady-state inactivation curve of the Ca2+ current from -20.7+/-0.65 to -26.7+/-1 mV (P<0.001, n=8) without changing its slope factor. These effects of fluoxetine developed rapidly and were fully reversible. Fluoxetine did not alter voltage-dependence of activation or time constant for inactivation of I(Ca). Fluoxetine had no effect on the amplitude of K+ currents (I(K1) and I(to)). The inhibition of cardiac Ca2+ and Na+ channels by fluoxetine may explain most cardiac side effects observed occasionally with the drug. Our results suggest that fluoxetine may have antiarrhythmic (class I + IV type), as well as proarrhythmic properties (due to impairment of atrioventricular or intraventricular conduction and shortening of repolarization). Therefore, in depressed patients with cardiac disorders, ECG control may be suggested during fluoxetine therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651149     DOI: 10.1007/s002109900154

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.

Authors:  Marion Aubert; Rolf Osterwalder; Björn Wagner; Isabelle Parrilla; Icilio Cavero; Lucette Doessegger; Eric A Ertel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Fluoxetine blocks Nav1.5 channels via a mechanism similar to that of class 1 antiarrhythmics.

Authors:  Hugo Poulin; Iva Bruhova; Quadiri Timour; Olivier Theriault; Jean-Martin Beaulieu; Dominique Frassati; Mohamed Chahine
Journal:  Mol Pharmacol       Date:  2014-07-15       Impact factor: 4.436

3.  Effects of SEA0400 and KB-R7943 on Na+/Ca2+ exchange current and L-type Ca2+ current in canine ventricular cardiomyocytes.

Authors:  Péter Birinyi; Károly Acsai; Tamás Bányász; András Tóth; Balázs Horváth; László Virág; Norbert Szentandrássy; János Magyar; András Varró; Ferenc Fülöp; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-08-06       Impact factor: 3.000

4.  Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports.

Authors:  Christopher Kogut; Ericka Breden Crouse; W Victor R Vieweg; Mehrul Hasnain; Adrian Baranchuk; Geneviève C Digby; Jayanthi N Koneru; Antony Fernandez; Anand Deshmukh; Jules C Hancox; Ananda K Pandurangi
Journal:  Ther Adv Drug Saf       Date:  2013-10

5.  Effects of tacrolimus on action potential configuration and transmembrane ion currents in canine ventricular cells.

Authors:  László Szabó; Norbert Szentandrássy; Kornél Kistamás; Bence Hegyi; Ferenc Ruzsnavszky; Krisztina Váczi; Balázs Horváth; János Magyar; Tamás Bányász; Balázs Pál; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-19       Impact factor: 3.000

6.  Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.

Authors:  János Magyar; Norbert Szentandrássy; Tamás Bányász; Valéria Kecskeméti; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-26       Impact factor: 3.000

Review 7.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

Review 8.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

9.  Sudden death in patients receiving drugs tending to prolong the QT interval.

Authors:  Kate Jolly; Michael D Gammage; Kar Keung Cheng; Peter Bradburn; Miriam V Banting; Michael J S Langman
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

10.  Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.

Authors:  J C Hancox; J S Mitcheson
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.